健康元：健康元药业集团股份有限公司2023年半年度报告（英文版）.PDF

1、Joincare Pharmaceutical Group Industry Co.,Ltd.Interim Report 2023 1/265 Joincare Pharmaceutical Group Industry Co.,Ltd.Interim Report 2023 2/265 Important Notice The Board of Directors(the“Board”),the Board of Supervisors and directors,supervisors and senior management of the Company hereby warrant

2、 the truthfulness,accuracy and completeness of the contents of the interim report(the“Report”),and that there are no false representations,misleading statements or material omissions contained in the Report,and severally and jointly accept responsibility.All the directors of the Company attended the

3、 Board meeting.The interim report of the Company is unaudited.Mr.Zhu Baoguo(朱保国朱保国),the person-in-charge of the Company,and Mr.Qiu Qingfeng(邱庆邱庆丰丰),the person-in-charge of the Companys accounting work and the person-in-charge of the accounting department(the head of the accounting department),declar

4、e that they hereby warrant the truthfulness,accuracy and completeness of the financial statements contained in the Report.Profit distribution plan or plan for conversion of capital reserve to share capital approved by the Board during the Reporting Period Not applicable VI Risk declaration for the f

5、orward-looking statements Applicable N/A The Report contains forward-looking statements which involve the future plans,development strategies,etc.of the Company,yet do not constitute substantive undertakings of the Company to investors.Investors should exercise caution prior to making investment dec

6、isions.VII Whether there is non-operating use of funds by the controlling shareholder and their related parties No VIII Whether there is a violation of the prescribed decision-making procedures to provide external guarantees No IX Whether more than half of directors cannot warrant the truthfulness,a